Pod Save America Hosts Call on Democrats to Cut All Israel Military Aid, No Longer Accept AIPAC Funding
Jews, Israelis Targeted in Austria Amid Surge in Antisemitic Incidents; Local Jewish Community Calls for Action
‘All of Our Strength’: Over 1,000 Pro-Israel Activists Gather in DC for Solidarity Conference
‘Devastated’: Wesley LePatner, Killed in Manhattan Mass Shooting, Was a Jewish Communal, Philanthropic Leader
Sen. Angus King Vows to No Longer Vote for Israel Military Aid Until Gaza Conditions Improve
Europe Won’t Pressure Israel to ‘Commit Suicide’ Amid Gaza Backlash, Palestinian State Push, Says Israeli FM
Israel’s National Soccer Coach Attacked in Athens Before Soccer Fans Chant ‘F–K Israel, Free Palestine’ at Match
New York Judge Sentences Neo-Nazi to 5 Years for Livestreaming Bomb Threats Against Jewish Hospitals
US Pressures Lebanon to Issue Cabinet Decision to Disarm Hezbollah Before Talks Continue
UK Plans to Recognize Palestinian State in September Unless Israel Meets Conditions, Starmer Says
Israel Nears Deal for AstraZeneca’s COVID-19 Vaccine
Error: Contact form not found.
by Reuters and Algemeiner Staff
AstraZeneca’s logo is reflected in a drop on a syringe needle, in this illustration, taken on Nov. 9, 2020. Photo: Reuters / Dado Ruvic / Illustration / File.
Israel has reached an understanding with AstraZeneca to receive about 10 million doses of its experimental COVID-19 vaccine, a joint statement from the Israeli government and the drugmaker said on Friday.
Details of the agreement were being finalized, the statement said, without giving an expected signing date.
An initial supply is expected to arrive in Israel in the first half of 2021, subject to approval by regulatory authorities in Europe, the United States and Israel, the statement said.
The vaccine being developed by AstraZeneca and its partner Oxford University is likely to be a two-dose course of treatment, meaning that 10 million doses would cover more than half of Israel‘s population of 9 million.
“This is a historic agreement led by the company’s local representation that will enable access to the vaccine for millions of Israeli citizens,” said Ohad Goldberg, chief executive of AstraZeneca Israel.
Data published on Thursday showed AstraZeneca’s vaccine candidate produced a strong immune response in older adults. Researchers are expected to release late-stage trial results by Christmas.
Israel has cast a wide net in its quest for access to a coronavirus vaccine. It has signed supply agreements with Pfizer and Moderna, and is in talks with Russia for its Sputnik V vaccine.
Israel is also developing its own vaccine that, if successful, could be ready for sale by the end of the summer.
